Despite impressive initial CD19 CAR T cell responses of up to 80% determined by 5-year overall survival, there is growing evidence of relapse due to antigen escape, with reports that 7–33% of responders in B-ALL relapse with CD19-negative tumours [35,71]. Here, CD19 is linked to acute lymphoblastic leukemia.